Cannabis Suisse Financials

CSUI

Source SEC Filings (10-K/10-Q) Updated Feb 28, 2026 Currency USD FYE May

This page shows Cannabis Suisse (CSUI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CSUI FY2025 2026-04-22

Tiny revenue and near-zero gross profit mean the company is running mainly on external funding, not customer cash.

In FY2025, net loss was -$456K but operating cash flow was only -$45K; paired with rising liabilities since FY2023, that gap says the recent accounting loss is much larger than the immediate cash drain, yet the business still is not funding itself through sales. Liabilities rose from $676K to $2.44M from FY2023 to FY2025, reinforcing that the buffer has come from the balance sheet rather than from internally generated cash.

FY2025 gross profit was effectively zero, while SG&A reached $229K; even before financing costs, the business is not covering its overhead. Interest expense of $63K then widens the gap, so current scale is the main constraint rather than a one-off cost spike.

Cash fell from $28.6K to $2.9K from FY2024 to FY2025, which reduced day-to-day flexibility. At the same time, long-term debt reached $611K and negative equity deepened, so the balance sheet is becoming more creditor-funded. A current ratio of 0.3x means short-term obligations are not buffered by a large pool of liquid current assets.

Financial Health Signals

Financial Profile 26/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Cannabis Suisse's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Cannabis Suisse has an operating margin of -1280.1%, meaning the company retains $-1280 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -856.5% the prior year.

Growth

100

Cannabis Suisse's revenue declined 25% year-over-year, from $30K to $23K. This contraction results in a growth score of 100/100.

Leverage

Cannabis Suisse has a moderate D/E ratio of -0.34. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity

Cannabis Suisse's current ratio of 0.33 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Neutral

4/9

Cannabis Suisse passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.10x

For every $1 of reported earnings, Cannabis Suisse generates $0.10 in operating cash flow (-$45K OCF vs -$456K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.6x

Cannabis Suisse earns $-4.6 in operating income for every $1 of interest expense (-$288K vs $63K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$23K

YoY-25.0%

5Y CAGR-37.9%

Cannabis Suisse generated $23K in revenue in fiscal year 2025. This represents a decrease of 25.0% from the prior year.

EBITDA

-$284K

YoY-12.3%

Cannabis Suisse's EBITDA was -$284K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.3% from the prior year.

Net Income

-$456K

YoY+61.6%

Cannabis Suisse reported -$456K in net income in fiscal year 2025. This represents an increase of 61.6% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3K

YoY-90.0%

5Y CAGR+255.8%

Cannabis Suisse held $3K in cash against $611K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

1.9%

YoY+2.1pp

5Y CAGR+36.9pp

Cannabis Suisse's gross margin was 1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the prior year.

Operating Margin

-1280.1%

YoY-423.6pp

5Y CAGR-1135.3pp

Cannabis Suisse's operating margin was -1280.1% in fiscal year 2025, reflecting core business profitability. This is down 423.6 percentage points from the prior year.

Net Margin

-2027.3%

YoY+1928.1pp

5Y CAGR-1866.9pp

Cannabis Suisse's net profit margin was -2027.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1928.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

CSUI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$23K-25.0%	$30K+200.0%	$10K+28.7%	$8K-84.7%	$51K-79.1%	$243K
Cost of Revenue	$22K-26.6%	$30K+228.0%	$9K+428.6%	$2K-98.3%	$103K-68.7%	$328K
Gross Profit	$432+744.8%	-$67-108.0%	$834-86.2%	$6K+111.7%	-$52K+38.9%	-$85K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$229K+30.9%	$175K+187.8%	$61K-55.2%	$136K	N/A	$174K
Operating Income	-$288K-12.1%	-$257K+25.0%	-$343K-118.1%	-$157K	N/A	-$351K
Interest Expense	$63K+135.8%	$27K+202.3%	$9K-86.1%	$64K+5.4%	$60K	N/A
Income Tax	$0	$0	$0	$0	$0	N/A
Net Income	-$456K+61.6%	-$1.2M-237.5%	-$352K-87.1%	-$188K	N/A	-$389K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$0	$0	$0	$0-100.0%	$8K0.0%	$8K0.0%	$8K0.0%	$8K
Cost of Revenue	$0	$0	$0	$0-100.0%	$7K0.0%	$7K0.0%	$7K-22.1%	$9K
Gross Profit	$0	$0	$0	$0-100.0%	$1440.0%	$1440.0%	$144+107.4%	-$2K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$59K-6.6%	$63K+0.6%	$62K-0.9%	$63K+13.3%	$56K+0.7%	$55K+0.6%	$55K-20.2%	$69K
Operating Income	-$69K+7.4%	-$75K+11.3%	-$85K-56.3%	-$54K+19.0%	-$67K+27.6%	-$92K-23.3%	-$75K+9.6%	-$83K
Interest Expense	$16K-1.1%	$16K-1.1%	$16K0.0%	$16K+2.2%	$16K-1.1%	$16K+8.6%	$15K+10.4%	$13K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$27K+20.2%	$22K+61.0%	$14K-68.7%	$44K+50.3%	$30K+483.1%	$5K+100.9%	-$535K+46.4%	-$999K
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$0.00	$0.00+100.0%	$-0.01	N/A

CSUI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$635K-29.2%	$897K+158.9%	$346K	$0-100.0%	$7K-98.3%	$384K
Current Assets	$107K-45.6%	$196K+4080.7%	$5K	$0-100.0%	$2K-98.6%	$157K
Cash & Equivalents	$3K-90.0%	$29K+14252.8%	$199	$0	$0-100.0%	$5
Inventory	N/A	N/A	N/A	$0-100.0%	$2K-97.0%	$58K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$77K
Goodwill	N/A	N/A	N/A	N/A	N/A	$0
Total Liabilities	$2.4M+8.7%	$2.2M+231.8%	$676K+146.5%	$274K+41.2%	$194K-74.8%	$770K
Current Liabilities	$326K-14.6%	$381K+14.1%	$334K+21.8%	$274K+41.2%	$194K-72.2%	$698K
Long-Term Debt	$611K+43.8%	$425K	N/A	N/A	N/A	$69K
Total Equity	-$1.8M-33.9%	-$1.3M-308.5%	-$329K-20.2%	-$274K-46.2%	-$187K+51.5%	-$387K
Retained Earnings	-$3.1M-17.5%	-$2.6M-83.9%	-$1.4M-33.1%	-$1.1M-21.5%	-$875K-92.1%	-$455K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$456K-10.6%	$510K-10.6%	$570K-10.2%	$635K-8.1%	$691K-8.1%	$752K-9.8%	$834K-7.0%	$897K
Current Assets	$66K-13.2%	$76K-14.2%	$88K-17.2%	$107K-9.4%	$118K-12.7%	$135K-22.7%	$175K-11.1%	$196K
Cash & Equivalents	$75-97.1%	$3K+760.7%	$305-89.3%	$3K+5600.0%	$50-98.8%	$4K-84.1%	$26K-9.9%	$29K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M-3.6%	$2.3M-3.5%	$2.4M-3.2%	$2.4M-4.0%	$2.5M-3.4%	$2.6M-3.2%	$2.7M+21.1%	$2.2M
Current Liabilities	$423K+7.9%	$392K+8.5%	$362K+11.1%	$326K+4.6%	$311K+11.7%	$279K+17.7%	$237K-37.8%	$381K
Long-Term Debt	N/A	N/A	N/A	$611K0.0%	$611K0.0%	$611K0.0%	$611K+43.8%	$425K
Total Equity	-$1.7M+1.5%	-$1.8M+1.3%	-$1.8M+0.8%	-$1.8M+2.4%	-$1.8M+1.6%	-$1.9M+0.3%	-$1.9M-39.8%	-$1.3M
Retained Earnings	-$3.0M+0.9%	-$3.0M+0.7%	-$3.0M+0.5%	-$3.1M+1.4%	-$3.1M+0.9%	-$3.1M+0.2%	-$3.1M-20.6%	-$2.6M

CSUI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$45K+1.2%	-$46K+72.2%	-$164K-411.0%	-$32K+75.4%	-$131K+54.8%	-$289K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	N/A	N/A	$0
Financing Cash Flow	$19K-73.8%	$74K-54.9%	$164K+411.6%	$32K-75.4%	$131K-36.7%	$206K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$18K+15.4%	-$21K-79.1%	-$12K-25.5%	-$9K+19.7%	-$11K+40.2%	-$19K-259.8%	-$5K-1210.3%	-$406
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	$0	$0	$0	$0	$0
Financing Cash Flow	$15K-35.0%	$23K+155.6%	$9K-25.0%	$12K+62.2%	$7K+396.0%	-$3K-200.0%	$3K-91.4%	$29K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CSUI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	1.9%+2.1pp	-0.2%-8.6pp	8.3%-69.3pp	77.7%+179.5pp	-101.9%-66.9pp	-34.9%
Operating Margin	-1280.1%-423.6pp	-856.5%+2570.4pp	-3426.8%-1404.2pp	-2022.6%	N/A	-144.7%
Net Margin	-2027.3%+1928.1pp	-3955.4%-439.9pp	-3515.5%-1097.3pp	-2418.2%	N/A	-160.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-71.8%+60.5pp	-132.3%-30.8pp	-101.5%	N/A	N/A	-101.5%
Current Ratio	0.33-0.2	0.52+0.5	0.01+0.0	0.00-0.0	0.01-0.2	0.23
Debt-to-Equity	-0.34-0.0	-0.32+1.7	-2.05-1.1	-1.00+0.0	-1.03-0.9	-0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	1.9%	N/A	N/A	N/A	1.9%0.0pp	1.9%0.0pp	1.9%+27.8pp	-25.9%
Operating Margin	-925.3%	N/A	N/A	N/A	-890.5%+340.3pp	-1230.8%-232.9pp	-997.9%+105.6pp	-1103.4%
Net Margin	358.8%	N/A	N/A	N/A	393.5%+326.0pp	67.5%+7202.0pp	-7134.5%+6186.6pp	-13321.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	5.9%+1.5pp	4.4%+1.9pp	2.4%-4.5pp	7.0%+2.7pp	4.3%+3.6pp	0.7%+64.8pp	-64.2%+47.3pp	-111.4%
Current Ratio	0.16-0.0	0.19-0.1	0.24-0.1	0.33-0.1	0.38-0.1	0.48-0.3	0.74+0.2	0.52
Debt-to-Equity	-1.26+0.0	-1.29+0.0	-1.32-1.0	-0.340.0	-0.330.0	-0.330.0	-0.320.0	-0.32
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.33), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Broad Street BRST

$319K

Metrospaces Inc MSPC

$2.9M

Blaqclouds Inc BCDS

$3.9M

Medican Enterpri MDCN

$4.7M

Nationwide RV and Resorts Inc NWRV

$4.8M

Frequently Asked Questions

What is Cannabis Suisse's annual revenue?

Cannabis Suisse (CSUI) reported $23K in total revenue for fiscal year 2025. This represents a -25.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cannabis Suisse's revenue growing?

Cannabis Suisse (CSUI) revenue declined by 25% year-over-year, from $30K to $23K in fiscal year 2025.

Is Cannabis Suisse profitable?

No, Cannabis Suisse (CSUI) reported a net income of -$456K in fiscal year 2025, with a net profit margin of -2027.3%.

What is Cannabis Suisse's EBITDA?

Cannabis Suisse (CSUI) had EBITDA of -$284K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cannabis Suisse have?

As of fiscal year 2025, Cannabis Suisse (CSUI) had $3K in cash and equivalents against $611K in long-term debt.

What is Cannabis Suisse's gross margin?

Cannabis Suisse (CSUI) had a gross margin of 1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cannabis Suisse's operating margin?

Cannabis Suisse (CSUI) had an operating margin of -1280.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cannabis Suisse's net profit margin?

Cannabis Suisse (CSUI) had a net profit margin of -2027.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cannabis Suisse's operating cash flow?

Cannabis Suisse (CSUI) generated -$45K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cannabis Suisse's total assets?

Cannabis Suisse (CSUI) had $635K in total assets as of fiscal year 2025, including both current and long-term assets.

What is Cannabis Suisse's current ratio?

Cannabis Suisse (CSUI) had a current ratio of 0.33 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Cannabis Suisse's debt-to-equity ratio?

Cannabis Suisse (CSUI) had a debt-to-equity ratio of -0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cannabis Suisse's return on assets (ROA)?

Cannabis Suisse (CSUI) had a return on assets of -71.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cannabis Suisse's cash runway?

Based on fiscal year 2025 data, Cannabis Suisse (CSUI) had $3K in cash against an annual operating cash burn of $45K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Cannabis Suisse's debt-to-equity ratio negative or unusual?

Cannabis Suisse (CSUI) has negative shareholder equity of -$1.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Cannabis Suisse's Piotroski F-Score?

Cannabis Suisse (CSUI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cannabis Suisse's earnings high quality?

Cannabis Suisse (CSUI) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cannabis Suisse cover its interest payments?

Cannabis Suisse (CSUI) has an interest coverage ratio of -4.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cannabis Suisse?

Cannabis Suisse (CSUI) scores 26 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.